GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 223 filers reported holding GENMAB A/S in Q4 2020. The put-call ratio across all filers is 1.46 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $377,407 | -6.0% | 10,701 | +1.3% | 0.06% | 0.0% |
| Q2 2023 | $401,652 | +3.6% | 10,567 | +2.9% | 0.06% | -4.8% |
| Q1 2023 | $387,720 | -9.9% | 10,268 | +1.2% | 0.06% | -17.1% |
| Q4 2022 | $430,115 | +12.3% | 10,149 | -14.8% | 0.08% | 0.0% |
| Q3 2022 | $383,000 | +52.6% | 11,908 | +53.9% | 0.08% | +58.3% |
| Q2 2022 | $251,000 | -26.0% | 7,736 | -17.5% | 0.05% | -30.4% |
| Q1 2022 | $339,000 | -2.9% | 9,372 | +6.3% | 0.07% | -1.4% |
| Q4 2021 | $349,000 | -20.0% | 8,820 | -11.5% | 0.07% | -28.6% |
| Q3 2021 | $436,000 | +35.4% | 9,970 | +26.3% | 0.10% | +28.9% |
| Q2 2021 | $322,000 | +1.3% | 7,896 | -18.6% | 0.08% | -14.6% |
| Q1 2021 | $318,000 | -22.6% | 9,699 | -4.0% | 0.09% | -26.4% |
| Q4 2020 | $411,000 | +15.8% | 10,107 | +4.3% | 0.12% | -5.5% |
| Q3 2020 | $355,000 | +2.3% | 9,691 | -5.4% | 0.13% | -6.6% |
| Q2 2020 | $347,000 | – | 10,249 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |